{"filing":{"accession_number":"0001193125-26-338022","cik":"0001661181","ticker":"ORGO","company_name":"Organogenesis Holdings Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"orgo-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1661181/000119312526338022/orgo-20260806.htm"},"events":[{"id":25631,"run_id":23262,"accession_number":"0001193125-26-338022","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a clear earnings release disclosing Organogenesis's Q2 2026 financial results via press release furnished as Exhibit 99.1. The filing reports net revenue of $42.8 million (down 58% YoY), net loss of $96.3 million (vs. $9.4 million loss in Q2 2025), and significantly reduced full-year 2026 guidance (62-68% revenue decline). The material deterioration in financial performance—including a $86.9 million increase in net loss and substantial revenue contraction—would affect a reasonable investor's assessment of the company.","company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26515,"accession_number":"0001193125-26-338022","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Organogenesis's Q2 2026 financial results via press release furnished as Exhibit 99.1. The filing reports net revenue of $42.8 million (down 58% YoY), net loss of $96.3 million (vs. $9.4 million loss in Q2 2025), and significantly reduced full-year 2026 guidance (62-68% revenue decline). The material deterioration in financial performance—including a $86.9 million increase in net loss and substantial revenue contraction—would affect a reasonable investor's assessment of the company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:18:39.261019+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26515,"accession_number":"0001193125-26-338022","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Organogenesis's Q2 2026 financial results via press release furnished as Exhibit 99.1. The filing reports net revenue of $42.8 million (down 58% YoY), net loss of $96.3 million (vs. $9.4 million loss in Q2 2025), and significantly reduced full-year 2026 guidance (62-68% revenue decline). The material deterioration in financial performance—including a $86.9 million increase in net loss and substantial revenue contraction—would affect a reasonable investor's assessment of the company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:18:39.261019+00:00","company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","filing_date":"2026-08-06"}]}